Surrozen
Surrozen, Inc.
Surrozen, Inc. is a biotechnology firm headquartered in South San Francisco, California, dedicated to pioneering innovative regenerative medicines through the activation of the Wnt signaling pathway. This critical mechanism serves as a foundation for tissue repair and regeneration, positioning Surrozen at the forefront of advanced therapeutic solutions for diverse medical conditions.
Products & Team
SZN-1326
SZN-1326 is a Fzd5-targeted antibody specifically designed to treat moderate to severe ulcerative colitis by stimulating Wnt signaling in the intestinal epithelium, thereby promoting tissue repair and healing.
SZN-1326 addresses the insufficient and often ineffective tissue repair mechanisms in patients with ulcerative colitis, which is crucial for improving the quality of life in these individuals.
These patients often face significant unmet medical needs due to the limitations of existing treatments, prompting the need for innovative solutions that can effectively promote tissue regeneration.